Sequoia helps fuel Whole Biome's planned launch for 'medical probiotics' in $35M Series B
Image: Colleen Cutcliffe WHOLE BIOME
The boom in microbiome therapeutics has elevated the “good” gut bacteria from probiotics to drug status, spurring some upstarts backed by prominent venture investors to take their therapies on the highly regulated journey toward an FDA approval. But Whole Biome wants to go a separate direction by occupying the middle ground with what it’s calling “medical probiotics.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
